Postoperative Adjuvant TACE Treatment in CK18 Positive Patients

Completed

• Conditions: Postoperative Adjuvant TACE; Hepatocellular Carcinoma.

• Registration Number: NCT02724345
• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital

Brief Summary

To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01
• Primary Completion: 2015-06
• Study Completion: 2015-12
• Status Verified: 2016-03
• Study First Submitted: 2016-03-28
• Study First Submitted QC: 2016-03-28
• Last Update Submitted: 2016-03-28
• Study First Posted: 2016-03-31
• Last Update Posted: 2016-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

1. Via clinical diagnosis and confirm it is primary liver cancer
2. Pathological evidence of HCC
3. Estimate tumor can gain treatment of curing operation
4. No evidence for extrahepatic metestasis
5. liver function ：Child-Pugh A/B

Exclusion Criteria

1. reject to attend；
2. impossible to come to our hospital for physical examination regularly.
3. cancer epitome、seed focus、lymph node or distant metastasis
4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	3 years

Secondary Outcome Measures

Name	Time	Method
Time to recurrence	3 years

Trial Locations

Locations (1)

Eastern hepatobilliary surgery hospital; 🇨🇳 Shanghai, Shanghai, China